Á lódáil...
Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
BACKGROUND: Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imat...
Na minha lista:
Foilsithe in: | J Immunother Cancer |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , , , |
Formáid: | Artigo |
Teanga: | Inglês |
Foilsithe: |
BioMed Central
2017
|
Ábhair: | |
Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5394629/ https://ncbi.nlm.nih.gov/pubmed/28428884 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-017-0238-1 |
Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|